These findings suggest that miR‐204 impedes T‐ALL growth and metastasis by targeting IRAK1 and highlight the potential role of miR‐204/NF‐κB signal pathway in targeted therapy of T‐ALL patients. The gene discussed is NFKB1; the disease is acute lymphoblastic leukemia.